Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Gets Price Target Cut from UBS Group

Syndax Pharmaceuticals logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • UBS cut its price target on Syndax Pharmaceuticals to $31 from $33 but maintained a Buy rating, implying roughly 243% upside from the stock’s then-current price of $9.04.
  • Analyst sentiment remains mostly positive: 10 analysts rate the stock Buy and one rates it Sell, with a consensus Moderate Buy rating and a $41.40 average price target.
  • Syndax’s latest quarterly revenue rose 81.9% year over year to $83.3 million, topping estimates, while its loss per share of $0.55 was wider than expected.
  • MarketBeat previews top five stocks to own in December.

Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) had its price objective lowered by UBS Group from $33.00 to $31.00 in a research report issued on Friday, Benzinga reports. The firm presently has a "buy" rating on the stock. UBS Group's price objective suggests a potential upside of 242.92% from the company's current price.

A number of other equities research analysts have also recently commented on SNDX. Jefferies Financial Group reissued a "buy" rating and issued a $35.00 price objective on shares of Syndax Pharmaceuticals in a research note on Tuesday, September 29th. Bank of America reiterated a "buy" rating on shares of Syndax Pharmaceuticals in a research note on Wednesday, August 5th. JPMorgan Chase & Co. dropped their price target on shares of Syndax Pharmaceuticals from $44.00 to $40.00 and set an "overweight" rating on the stock in a research report on Tuesday, August 11th. HC Wainwright lowered their target price on Syndax Pharmaceuticals from $38.00 to $36.00 and set a "buy" rating on the stock in a research note on Tuesday, November 3rd. Finally, Weiss Ratings raised shares of Syndax Pharmaceuticals from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Tuesday, November 3rd. Ten investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Syndax Pharmaceuticals has a consensus rating of "Moderate Buy" and a consensus price target of $41.40.

Read Our Latest Stock Analysis on Syndax Pharmaceuticals

Syndax Pharmaceuticals Price Performance

SNDX traded down $0.09 during midday trading on Friday, hitting $9.04. 888,200 shares of the company traded hands, compared to its average volume of 1,884,865. Syndax Pharmaceuticals has a 52-week low of $8.41 and a 52-week high of $25.59. The company has a current ratio of 4.69, a quick ratio of 4.37 and a debt-to-equity ratio of 38.95. The business has a 50 day simple moving average of $14.41 and a two-hundred day simple moving average of $19.50. The company has a market capitalization of $813.85 million, a price-to-earnings ratio of -3.83 and a beta of 0.48.

Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) last posted its earnings results on Monday, November 2nd. The company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.50) by ($0.05). Syndax Pharmaceuticals had a negative net margin of 72.32% and a negative return on equity of 804.38%. The company had revenue of $83.30 million during the quarter, compared to analyst estimates of $81.38 million. During the same quarter last year, the business posted ($0.70) EPS. The firm's revenue for the quarter was up 81.9% on a year-over-year basis. On average, equities analysts forecast that Syndax Pharmaceuticals will post -2.09 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, Director Dennis Podlesak sold 8,000 shares of the company's stock in a transaction dated Thursday, October 29th. The stock was sold at an average price of $14.21, for a total transaction of $113,680.00. Following the sale, the director owned 239,763 shares in the company, valued at approximately $3,407,032.23. This represents a 3.23% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Company insiders own 4.80% of the company's stock.

Institutional Investors Weigh In On Syndax Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in SNDX. Algert Global LLC boosted its stake in shares of Syndax Pharmaceuticals by 5.9% in the 3rd quarter. Algert Global LLC now owns 1,113,607 shares of the company's stock valued at $20,936,000 after purchasing an additional 62,142 shares in the last quarter. Jump Financial LLC grew its position in shares of Syndax Pharmaceuticals by 31.7% during the 3rd quarter. Jump Financial LLC now owns 530,466 shares of the company's stock worth $9,973,000 after buying an additional 127,620 shares during the period. Apis Capital Advisors LLC lifted its holdings in shares of Syndax Pharmaceuticals by 8.8% in the 3rd quarter. Apis Capital Advisors LLC now owns 605,000 shares of the company's stock worth $11,374,000 after purchasing an additional 49,000 shares in the last quarter. Marshall Wace LLP acquired a new stake in shares of Syndax Pharmaceuticals in the 3rd quarter worth about $368,000. Finally, Bleakley Financial Group LLC purchased a new stake in shares of Syndax Pharmaceuticals during the third quarter valued at approximately $299,000.

About Syndax Pharmaceuticals

(Get Free Report)

Syndax Pharmaceuticals is a biotechnology company focused on developing and commercializing medicines for cancer and related serious diseases. Its research programs include therapies that target cancer-driving pathways, including menin and the colony-stimulating factor 1 receptor (CSF-1R). The company's medicines include Revuforj (revumenib), approved in the United States for certain adults and children aged one year and older with relapsed or refractory acute leukemia involving a KMT2A translocation.

Further Reading

Analyst Recommendations for Syndax Pharmaceuticals (NASDAQ:SNDX)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Syndax Pharmaceuticals Right Now?

Before you consider Syndax Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Syndax Pharmaceuticals wasn't on the list.

While Syndax Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines